Dapagliflozin Gets Expanded Heart Failure Indication in Europe ...Middle East

The European Commission has expanded the indication of the SGLT2 inhibitor to include HF with mildly reduced and preserved ejection fraction, based on the DELIVER phase 3 trial. International Approvals

Hence then, the article about dapagliflozin gets expanded heart failure indication in europe was published today ( Thursday 09/02/2023 - 03:24 AM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Dapagliflozin Gets Expanded Heart Failure Indication in Europe )

Also on site :

• 2010s Rock Band Announces Tour for 10th Anniversary of Debut Album
• Nuclear neighbors and a two‑front threat: Why India needs a rocket force
• Greenland hit by power outage, strong winds in wake of US tensions easing